Jun 19,2023

Impact of Continuous Glucose Monitoring Initiation on Emergency Health Services Utilization

The study assessed the effects of continuous glucose monitoring initiation (Dexcom) on emergency department (ED) visits in diabetes patients using insulin. Results from a large health insurer in the southeastern U.S. showed a 14% lower incidence rate of ED visits for CGM initiators compared to non-initiators.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 06,2023 TOP STORY

Medicare now covers new Medtronic MiniMed 780G automated insulin pump

Medtronic announced today that Medicare now covers its new MiniMed 780G system with the Guardian 4 sensor. Coverage for the recently FDA-approved automated insulin delivery system extends to all eligible Medicare and Medicare Advantage beneficiaries. The company plans to start shipments to eligible recipients with type 1 diabetes over the next few weeks. The MiniMed 780G system features SmartGuard technology and Meal Detection Technology, providing automatic adjustments to sugar levels without fingersticks and optimizing insulin delivery. Medtronic presented positive data on the system's Meal Time Technology at the American Diabetes Association Scientific Sessions.

PRODUCT

#cgm

#insulin pump

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Jul 04,2023 TOP STORY

Dexcom G7 Receives Health Canada Approval

Health Canada has approved the Dexcom G7 Continuous Glucose Monitoring System for people with diabetes in Canada. The next-generation CGM system offers unmatched accuracy, simplicity, and improved diabetes management. Dexcom G7 aims to make glucose monitoring easier and has been shown to reduce hospitalizations and emergency room visits due to hypoglycemia. The system will be available in Canada by the end of 2023.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Rimidi and Boston Medical Center Release Metrics from Ongoing Remote Monitoring Program for Postpartum Hypertension

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, and Boston Medical Center, a private, not-for-profit academic medical center in New England, today released metrics from an ongoing remote patient monitoring program for new moms at high-risk of postpartum hypertension. Boston Medical Center leveraged the Rimidi platform to bring remotely-generated patient data from cellular-connected blood pressure cuffs into their clinical workflow. As part of Epic’s app orchard, Rimidi launches directly within the BMC team’s Epic experience. Resulting from the initial success of Boston Medical Center’s postpartum hypertension program, the center is now expanding the program to include monitoring for gestational hypertension, using cellular blood pressure cuffs and gestational diabetes, using cellular glucometers and FreeStyle Libre Continuous Glucose Monitors.

CLINICAL STUDY

#rpm

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Rimidi Showcases Addition of Glycemic Risk Index to Diabetes Management Platform, Announces Enhanced Integration with Dexcom

Rimidi announced today enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management. The inclusion of CGM data and GRI into Rimidi’s platform and clinical workflows is made possible via an enhanced integration with Dexcom, a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. Through the collaboration, glycemic control metrics will enable more proactive and personalized management of diabetes across populations to drive better care decisions. This metric can be used to assess how well a patient is doing over time, manage a population and predict outcomes in intervention studies. The composite score is also thought to better correlate with the risk of complications and help identify areas for therapy adjustment.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 27,2023

Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023

Nemaura Medical, a medical technology company, announces the pilot expansion of its proBEAT™ wearable sensor and AI-based feedback platform in the US. Over 50 corporations have signed up for pilots in June 2023. The program aims to provide cost-effective diabetes care solutions and personalized weight reduction programs. The company's innovation marks significant progress towards revenue generation and brings more innovative diabetes care solutions to the market.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

ABBOTT'S FREESTYLE LIBRE 2 RECEIVES NATIONAL REIMBURSEMENT IN FRANCE FOR ALL PEOPLE WITH DIABETES WHO USE INSULIN

Abbott's FreeStyle Libre 2 system has received national reimbursement in France for all individuals who use basal insulin as part of their diabetes management. FreeStyle Libre 2 was previously covered only for people with Type 1 and Type 2 diabetes who require intensive insulin therapy. France is the first European country to provide national reimbursement for basal insulin users, following similar expansions in Japan and the U.S. Medicare system.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More

Dexcom has unveiled plans to launch a new product with a 15-day wear period and include a cash-pay option, together with a new software experience tailored for people not on insulin in the U.S. in 2024. Dexcom's CGM technology is expanding globally, with availability in 14 countries and its recent entry into the Latin American market. Additionally, the company reported that the coverage for Dexcom CGM by private payers in the U.S. is increasing, following Medicare's lead. Projections suggest that millions of people with a history of problematic hypoglycemia are now covered for Dexcom CGM through Medicare.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

South Korea approves first local CGM device

The South Korean Ministry of Food and Drug Safety has approved the first locally-developed continuous glucose monitoring (CGM) device, the CareSens Air, developed by i-SENS. The device is small, light, and offers reliable readings. i-SENS plans to launch it in Q3 2023 and seeks CE clearance for the European market by H1 2024. This approval marks the fourth CGM device approved by the South Korean government, following foreign products by Medtronic, Abbott, and Dexcom.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

A Dual Function Glucose Sensing Insulin Delivery Technology Is Presented at the 83rd Scientific Sessions of the American Diabetes Association

One of the studies presented at the ADA conference in San Diego, CA was about the SynerG, a dual-function glucose sensing-insulin delivery device developed by Pacific Diabetes Technologies that simplifies diabetes management. The SynerG glucose sensor has a warm-up time of less than 30 min and also synchronizes replacement schedules for insulin delivery and glucose measurement functions. Feasibility of a Prototype Dual Function Glucose Sensing Insulin Delivery Cannula in People with Type 1 Diabetes, showed the feasibility of the first single through-the-skin device combining glucose sensing and insulin delivery functions (SynerG). The study enrolled 24 adults with type 1 diabetes on insulin pump therapy (IPT). The device was inserted subcutaneously in the anterior abdomen and attached to the pump, following a 48-hour run-in using a commercially available infusion set with a study pump. Findings for 24 participants indicate that insulin did not interfere with the function of the glucose sensor and demonstrated accuracy in the measurement of glucose. In addition, insulin was delivered reliably to participants.

CLINICAL STUDY

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM